Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA2 | P42262 | 1/20 | 0.84 |
| ▸ | SLC7A5 | Q01650 | 5/20 | 0.69 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.69 |
| ▸ | ALPI | P09923 | 1/20 | 0.69 |
| ▸ | PKM | P14618 | 1/20 | 0.69 |
| ▸ | XIAP | P98170 | 1/20 | 0.69 |
| ▸ | NOS3 | P29474 | 2/20 | 0.62 |
| ▸ | NOS1 | P29475 | 2/20 | 0.62 |
| ▸ | NOS2 | P35228 | 2/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | USP2 | O75604 | 1/20 | 0.59 |
| ▸ | EGFR | P00533 | 1/20 | 0.59 |
| ▸ | LCK | P06239 | 1/20 | 0.59 |
| ▸ | FYN | P06241 | 1/20 | 0.59 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.59 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.59 |
| ▸ | HTR2A | P28223 | 1/20 | 0.59 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.59 |
| ▸ | RECQL | P46063 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29217053 | 1.00 | GRIA2 (0.84) | GRIA2SLC7A5PTGS1ALPIPKM | |
| SCHEMBL31398345 | 0.96 | GRIA2 (0.79) | GRIA2SLC7A5PTGS1ALPIPKM | |
| SCHEMBL22190023 | 0.96 | GRIA2 (0.79) | GRIA2SLC7A5PTGS1ALPIPKM | |
| SCHEMBL16465139 | 0.96 | GRIA2 (0.79) | GRIA2SLC7A5PTGS1ALPIPKM | |
| SCHEMBL1904776 | 0.96 | GRIA2 (0.79) | GRIA2SLC7A5PTGS1ALPIPKM | |
| Hydrochloric Acid SCHEMBL7568949 | 0.95 | GRIA2 (0.77) | GRIA2SLC7A5PTGS1ALPIPKM | |
| Hydrochloric Acid SCHEMBL7568954 | 0.95 | GRIA2 (0.77) | GRIA2SLC7A5PTGS1ALPIPKM | |
| SCHEMBL31369541 | 0.91 | GRIA2 (0.71) | GRIA2SLC7A5PTGS1ALPIPKM | |
| SCHEMBL31370223 | 0.91 | GRIA2 (0.71) | GRIA2SLC7A5PTGS1ALPIPKM | |
| SCHEMBL31369781 | 0.91 | GRIA2 (0.71) | GRIA2SLC7A5PTGS1ALPIPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220112242-A1 | SOMATOSTATIN RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USING THE SAME | CDRD VENTURES INC. (CA) | 2022-04-14 | — | — | US | disclosed |
| US-11279732-B2 | Somatostatin receptor antagonist compounds and methods of using the same | CDRD VENTURES INC. (CA) | 2022-03-22 | — | — | US | disclosed |
| US-10905736-B2 | Ezetimibe-associated ApoA-I mimetic peptides showing enhanced synergism | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-02-02 | — | — | US | disclosed |
| EP-3143035-B1 | METHOD TO CONCENTRATE APOA-I MIMETIC PEPTIDES TRANSGENICALLY EXPRESSED IN PLANTS | UNIV CALIFORNIA (US) | 2019-08-07 | — | — | EP | disclosed |
| EP-2830414-B1 | MODULATING DISEASE THROUGH GENETIC ENGINEERING OF PLANTS | UNIV CALIFORNIA (US) | 2019-05-08 | — | — | EP | disclosed |
| US-20190040102-A1 | SOMATOSTATIN RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USING THE SAME | CDRD VENTURES INC. (CA) | 2019-02-07 | — | — | US | disclosed |
| EP-3414259-A1 | SOMATOSTATIN RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USING THE SAME | CDRD Ventures Inc. (CA) | 2018-12-19 | — | — | EP | disclosed |
| US-20180193479-A1 | MEDITOPES AND MEDITOPE-BINDING ANTIBODIES AND USES THEREOF | MEDITOPE LLC | 2018-07-12 | — | — | US | disclosed |
| WO-2018063796-A1 | EZETIMIBE-ASSOCIATED APOA-1 MIMETIC PEPTIDES SHOWING ENHANCED SYNERGISM | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-04-05 | — | — | WO | disclosed |
| US-20180085420-A1 | EZETIMIBE-ASSOCIATED APOA-I MIMETIC PEPTIDES SHOWING ENHANCED SYNERGISM | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2018-03-29 | — | — | US | disclosed |
| WO-2005034989-A2 | USE OF SOMATOSTATIN OR ONE OF THE ANALOGS THEREOF FOR PRODUCING A MEDICAMENT SERVING TO REGULATE THE OVARIAN FOLLICULAR RESERVE IN NON-MENOPAUSAL WOMEN | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (I.N.S.E.R.N) (FR) | 2005-04-21 | — | — | WO | disclosed |
| EP-1522311-A1 | Use of somatostatin or analogs thereof for the preparation of a medicament for the regulation of ovarian follicles reserve by non menopausaled women | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2005-04-13 | — | — | EP | disclosed |
| US-20040181032-A1 | Somatostatin antagonists | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND | 2004-09-16 | — | — | US | disclosed |
| US-20040097418-A1 | Somatostatin antagonists | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES, S.A.S. | 2004-05-20 | — | — | US | disclosed |
| US-6703481-B1 | USE OF PEPTIDES INCORPORATING D-AMINO ACID TO PROMOTE THE RELEASE OF GROWTH HORMONE OR INSULIN, ENHANCING WOUND HEALING OR PROMOTING ANGIOGENESIS | THE ADMINISTRATION OF THE TULANE EDUCATIONAL FUND | 2004-03-09 | — | — | US | disclosed |
| EP-1372688-A2 | SOMATOSTATIN ANTAGONISTS | The Administrators of The Tulane Educational Fund (US) | 2004-01-02 | — | — | EP | disclosed |
| WO-2002072602-A2 | SOMATOSTATIN ANTAGONISTS | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2002-09-19 | — | — | WO | disclosed |
| US-6262229-B1 | OCTAPEPTIDES | BIOMEASURE INCORPORATED | 2001-07-17 | — | — | US | disclosed |
| EP-0956296-A2 | SOMATOSTATIN ANTAGONISTS | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 1999-11-17 | — | — | EP | disclosed |
| WO-1998024807-A2 | SOMATOSTATIN ANTAGONISTS | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES S.A. (S.C.R.A.S.) (FR) | 1998-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180193479-A1 | MEDITOPES AND MEDITOPE-BINDING ANTIBODIES AND USES THEREOF | FCGR3B, FCGR2A, FCGR1A | GRIA2 720/4885SLC7A5 4393/4885PTGS1 4290/4885 |
| US-20040181032-A1 | Somatostatin antagonists | SSTR4, SSTR1, SSTR5 | GRIA2 875/4885SLC7A5 222/4885PTGS1 4288/4885 |
| US-11279732-B2 | Somatostatin receptor antagonist compounds and methods of using the same | GPR119, SSTR5, SSTR2 | GRIA2 396/4885SLC7A5 1044/4885PTGS1 2666/4885 |
| US-20220112242-A1 | SOMATOSTATIN RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USING THE SAME | GPR119, SSTR5, SSTR2 | GRIA2 389/4885SLC7A5 1032/4885PTGS1 2711/4885 |
| US-20040097418-A1 | Somatostatin antagonists | SSTR5, SSTR2, SSTR4 | GRIA2 494/4885SLC7A5 218/4885PTGS1 4013/4885 |
| US-20190040102-A1 | SOMATOSTATIN RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USING THE SAME | GPR119, SSTR5, SSTR2 | GRIA2 396/4885SLC7A5 1044/4885PTGS1 2666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.